The 10 most commonly used long-term therapies at COVID-19 diagnosis were analgesics (21.5%), proton-pump inhibitors/anti-acids (18.4%), sedatives/hypnotics (16.7%), antidepressants (16.0%), anti-thrombotics (12.9%), lipid-modifying agents (12.2%), angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEi/ARBs) (11.4%), chronic obstructive pulmonary disease/asthma inhalers (10.4%), diuretics (8.4%) and beta-blockers (6.8%). This evidence concerns the gene ACE and COVID-19.